Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Apyx Medical (APYX) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Apyx Medical (APYX) over the last 15 years, with Q3 2025 value amounting to -$2.0 million.

  • Apyx Medical's Income from Continuing Operations rose 5861.56% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.5 million, marking a year-over-year increase of 4908.15%. This contributed to the annual value of -$23.6 million for FY2024, which is 2498.14% down from last year.
  • As of Q3 2025, Apyx Medical's Income from Continuing Operations stood at -$2.0 million, which was up 5861.56% from -$3.7 million recorded in Q2 2025.
  • Apyx Medical's Income from Continuing Operations' 5-year high stood at -$1.0 million during Q2 2023, with a 5-year trough of -$9.6 million in Q4 2023.
  • Moreover, its 5-year median value for Income from Continuing Operations was -$4.7 million (2023), whereas its average is -$4.8 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first skyrocketed by 8130.28% in 2023, then crashed by 54631.99% in 2024.
  • Over the past 5 years, Apyx Medical's Income from Continuing Operations (Quarter) stood at -$2.0 million in 2021, then tumbled by 201.74% to -$6.1 million in 2022, then plummeted by 58.68% to -$9.6 million in 2023, then surged by 51.59% to -$4.7 million in 2024, then soared by 58.04% to -$2.0 million in 2025.
  • Its Income from Continuing Operations stands at -$2.0 million for Q3 2025, versus -$3.7 million for Q2 2025 and -$4.2 million for Q1 2025.